Provided by Tiger Trade Technology Pte. Ltd.

AKESO

106.800
-1.900-1.75%
Volume:4.79M
Turnover:507.16M
Market Cap:98.36B
PE:-86.63
High:107.800
Open:105.200
Low:103.700
Close:108.700
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:0.36
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.233
ROE:-13.59%
ROA:-4.57%
PB:9.91
PE(LYR):-86.63
PS:24.38

Loading ...

Bank of Communications International Retains 'Buy' Rating for AKESO with HK$175 Target Price

Stock News
·
Jun 03

Stock Track | Akeso Plummets 5.07% Intraday on Profit-Taking After ASCO Data, US Investment Concerns

Stock Track
·
Jun 03

Movement Alert|Akeso Inc Falls 3.1% in Regular Trading, Biotech Sector Extends Post-ASCO Pullback as Profit-Taking Continues

Market Focus
·
Jun 03

CICC Reiterates Outperform Rating on AKESO with HK$184 Target Price

Stock News
·
Jun 02

Stock Track | AKESO Plummets 7.94% Intraday as Profit-Taking Follows ASCO Rally Amid Large Block Sale

Stock Track
·
Jun 02

Movement Alert|Akeso Inc Falls 4.49% in Regular Trading, Large Block Sale Triggers Profit-Taking After ASCO Rally

Market Focus
·
Jun 02

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Dow Jones
·
Jun 01

Major Volatility Hits Hong Kong Connect Innovative Drug Stocks: What Triggered the Sharp Turnaround?

Deep News
·
Jun 01

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

Mainland Investors Inject HK$4.66 Billion into Hong Kong Market; AKESO Leads with HK$2.7 Billion Inflow Following Positive OS Data

Stock News
·
Jun 01

CMSC Retains Strong Buy Rating on AKESO, Highlights Global Lung Cancer Market Potential

Stock News
·
Jun 01

AKESO's Landmark Clinical Data Ignites Stock Surge, Bolstering Hong Kong Connect Innovative Drug Sector

Deep News
·
Jun 01

Stock Track | AKESO Soars 9.74% Intraday on Positive Phase III Lung Cancer Trial Data at ASCO

Stock Track
·
Jun 01

Movement Alert|Akeso Rises 11.77% in Regular Trading, ASCO Plenary Session Data Shows Ivonescimab Beats PD-1 Combo in Overall Survival

Market Focus
·
Jun 01

AKESO Shares Surge on Positive Phase III Lung Cancer Trial Data

Stock News
·
Jun 01

AKESO Unveils Over 40 Clinical Trial Findings for Innovative Drugs at 2026 ASCO

Stock News
·
Jun 01

Akeso says Phase III HARMONi-6 trial shows ivonescimab-chemo cuts death risk 34% in first-line sq-NSCLC

Reuters
·
May 31

Harmoni-6 Demonstrates Significant Overall Survival Benefit (Hr=0.66): Ivonescimab Plus Chemotherapy Superior to Pd-1 Plus Chemotherapy in First-Line Sq-Nsclc Landmark Results to Be Presented at Asco 2026 Plenary Session

THOMSON REUTERS
·
May 31

CORRECTED-Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)

Reuters
·
May 31

Stock Track | AKESO Soars 5.07% Intraday as Ivonescimab Data Selected for ASCO Plenary Presentation

Stock Track
·
May 29